Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • Cells were treated with brefeldin A or manumycin A, and the resulting supernatant was collected after 48 h for exosomal preparation (lanes 1 and 2), or exosomes obtained from C81 cells were trypsin-treated or freeze/thawed (F/T) and then trypsin-treated (lanes 3 and 4). Lanes 5 and 6, input exosome controls from C81 or CEM cells, respectively. Resulting exosomes were assayed for the presence of Tax by Western blotting.

    J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 MnLMSpVv[3Srb36gRZN{[Xl? M3LlcVIh|ryP MW[xJIg> NVmxWWtYcW6qaXLpeJMhfGinIFytSG9RSSBqMkFCpO69VSlvaX7keYNm\CC2cnHud4lmdnRiRWLLNU8zKHCqb4PwbI9zgWyjdHnvcuKh MUOyOlM3OzF7MR?=
C2C12 M1rweWZ2dmO2aX;uJGF{e2G7 NVL3T2VXOcLizsznM41t NI\2NZIyyqCq MX\hZo9tcXOqZYOgZ5l1d2urbnWgdoVt\WG|ZTDmdo9uKEN{Q{GyJI16d3S3YnXz NHXBNoozPjJ7MUK3PS=>
MEFs WT M2rvd2Z2dmO2aX;uJGF{e2G7 MnLqOeKh|ryP MYqyNEBucW5? M37IPYNifXOnczDy[ZNq\GWwdDDlcpp6dWW|IIP1Z4gh[XNiTlHHWE1ITlBuIITvJIRq\m[3c3WgZoFkcyC2bzD0bIUhTVJ? MYqyOlE6PjB{Mx?=
MEFs VAMP7 KO NHviV3dHfW6ldHnvckBCe3OjeR?= Mk\3OeKh|ryP NVfRWZJmOjBibXnu NG\GNo9k[XW|ZYOgdoV{cWSnboSg[Y57gW2nczDzeYNpKGG|IF7BS3QuT0[SLDD0c{BlcW[odYPlJIJi[2tidH:geIhmKEWU NF\LUIYzPjF7NkCyNy=>
SMCs M1r6SWZ2dmO2aX;uJGF{e2G7 MormNVDDqML3Zz;tcC=> NXO2bpRJOC1zMjDo MUHEUXNQ MWHzbI94eyCjIITy[Y5lKHSxd3Hy[JMh[SCqaXfo[ZIh[2:wY3XueJJifGmxbjDv[kB1cGViRWKvV3IhdmW2d3;yb{BqdiC2aHWgdIVzcW63Y3zlZZIh[XKnYdMg M4T5SFI3OTd{MEiw
SMCs MVXGeY5kfGmxbjDBd5NigQ>? MWKxNOKhyrWpL33s NIHXVJoxNTF{IHi= MkX0SG1UVw>? NFPSN4lk[XW|ZYOgZUB1emGwc3nlcpQhS2F{K9MgdoVt\WG|ZTDmdo9uKHSqZTDFVk9UWsLi NV\iSVhvOjZzN{KwPFA>
HEMC-1 M3fSXWZ2dmO2aX;uJGF{e2G7 NGTkTmwxNjIEoNM1[{9udA>? MX2yOOKhcA>? NE\PVI5k[XW|ZYOgZUBpcWeqZYKgbY5pcWKrdH;yfUBm\m[nY4Sgc44h\XixY4n0c5NqeyC2aHHuJI5w[2:mYYrvcIU> MnPGNlU6PzJ5NUm=
HUVEC M2r6d2Z2dmO2aX;uJGF{e2G7 MnnLNVDDqM7:TR?= MW[xxsBp NITOV|hFVVOR M{\pNIFjd2yrc3jld{BpgXCxeHnhMYlv\HWlZXSgdoVt\WG|ZTDv[kBCXFBiZoLvcUBieGmlYXygZY5lKGKjc3;sZZRmemGuIIP1doZi[2W| MViyOVk2Pjl6OB?=
HUVEC NIHjTllHfW6ldHnvckBCe3OjeR?= MUixNOKh|ryP M{KzPFHDqGh? M3z2OGROW09? M3Lnbolv[3KnYYPld:KhfGinIH71cYJmeiCjbnSgbY51\W6|aYT5JI9nKG[udX;y[ZNk\W62IHHy[YF{KGW|cHXjbYFtdHliaX6gdIVzcW63Y3zlZZIhe3CjY3W= NY[4cVhZOjV7NU[5PFg>
Caco-2 NFOwe2FHfW6ldHnvckBCe3OjeR?= M3TQc|IvPSEQvF2= NUXVb|ZIOzBibXnu NF7w[I1ifHSnboXheIV{KHSqZTDUS2Yu|rJzLX3l[IlifGWmIHnuZ5Jm[XOnIHnuJHNGWlRiZoXuZ5Rqd25? M2XNZ|I2QTV2OUOx
NRK NFLuT4dHfW6ldHnvckBCe3OjeR?= Mm\CNlAx6oDHbnevcYw> M{nXelTjiIWq NGe4fGVFVVOR M4T0WZJme2O3ZYOgcYl1d3SrYzDwdo9oemW|c3nvci=> NW[1ZW5YOjV7NEi1PFY>
HeLa NV;KdFBrTnWwY4Tpc44hSXO|YYm= M2K3eVIxOOLChX7nM41t MWWzJIg> NHvGeFhFVVOR NWjJ[IY{cW6mdXPld{B1cGViYYL0bYZq[2mjbDDidoVicy23cDDv[kB1cGViR3;s[4kh[2:vcHzlfC=> MUWyOVk1QDV6Nh?=
COS MV3GeY5kfGmxbjDBd5NigQ>? NUPBNFdyOSEQvHevcYw> NGD5T2w{KGh? MWXjc41xdGW2ZXz5JIRqe3CncoPld{B1cGViQWCtNUB{cWewYX|CpC=> M1HRfVI2QTF3OUCw
DF1  NF7ycVZHfW6ldHnvckBCe3OjeR?= M4mxdlHDqM7:TdMg MoL0OFghcA>? MX7EUXNQ MmHn[Il{eGW{c3XzxsB1cGViZYjv[4Vvd3W|IFPTS4FtVkGlVEKgdJJwfGWrbh?= M2T1OlI2QDB5MEW0
nHDFs  M4TZT2Z2dmO2aX;uJGF{e2G7 NHXiOFgyyqEQvF5CpC=> M1XyUlLDqGh? MmDwdJJmfmWwdIOgeIhmKGG|c3XtZox6KG:oIHP5eI9{d2yrYzDjc4F1KHC{b4TlbY5{KG:wdH:gS49t\2libXXtZpJidmW| M2TENFI2Pzd{NkG2
FRT  NV3HRmd[TnWwY4Tpc44hSXO|YYm= MkHxOUDPxGdxbXy= NEm1fVEzyqCq M1KzcIJtd2OtczD0doFn\mmla3nu[{B1cHKxdXfoJJRp\SCJb3znbUBkd22ybHX4JIJ6KGmwaHnibZRqdmdiRWKteI8uT2:uZ3mgeJJidnOyb4L0 M{jVTVI2PzZ5MUG1
FRT  Mm\iSpVv[3Srb36gRZN{[Xl? NYHhbnFTPSEQvHevcYw> MXWyxsBp MlzRdJJmfmWwdIOgeIhmKGmwY4LlZZNmKGmwIHPs[YF3\WRizsGgd5VjfW6rdIOge4hmdiCdTnGrYYnDqHejczDy[YR2[2Wm M3TTcVI2PzZ5MUG1
HepG2  M{jTTmZ2dmO2aX;uJGF{e2G7 MoD6NgKBkcL3TdMg NULvbHZoOjRiaB?= MXjEUXNQ NIroPVJl\WO{ZXHz[ZMhfGinIHzleoVtKG:oIGDYVkBuWk6D MV[yOVYyPjV7Nx?=
SMCs MlnrSpVv[3Srb36gRZN{[Xl? NYjvZ5cxOc7:Zz;tUC=> M2T0O|MhcA>? MYThZ4N2dXWuYYTld{BEVlC\MjDwdo91\WmwIHnuJJRp\SCHUjDjc41x[XK2bXXueEBidmRibn:gcI9v\2W{IHPvMYxw[2GuaYrl[EB4cXSqIITo[UBId2ypaTDtZZJs\XMEoB?= NUHwUY9XOjV3OEm0NlU>
OB-6 M{nIc2Fxd3C2b4Ppd{BCe3OjeR?= M4j1TlIvP8LizszN MnLWOFghcA>? MmW1bY5lfWOnczDhdI9xfG:|aYO= M{HpclI2PTN{NEiw
iPSC-CMs  MVTGeY5kfGmxbjDBd5NigQ>? MoTvOVAxKG6pL33s MVu0PEBp NGC2Zm5qdmO{ZXHz[ZMhfGinIHnueIVve2m2eTDv[kB1cGViaHnnbIVzKG2xYnnsbZR6KEyDTWDzJIF1KHSqZTDjc5N1KG:oIITo[UBtd3encjDtc4JqdGm2eTDzdIVkcWW| MVuyOVQ5QDZ4Nh?=
SP-Nluc NXK4W5JzTnWwY4Tpc44hSXO|YYm= MYq1JI1oN22O MWm2JIg> M4CxZ2ROW00EoB?= M2nWNYNifXOnczDhckBqdmO{ZXHz[UBqdiC{ZYDvdpRmeiCjY4Tpeol1gSCrbjD0bIUheGG{YYPpeIU> MljWNlU{QTJ7OUi=
PEXEL-Nluc NYLuOoxmTnWwY4Tpc44hSXO|YYm= M4HxdFUhdWdxbVy= NEfDUHY3KGh? NXvrb3pRTE2VT9Mg MYXjZZV{\XNiYX6gbY5kemWjc3WgbY4hemWyb4L0[ZIh[WO2aY\peJkhcW5idHjlJJBiemG|aYTl MXGyOVM6Ojl7OB?=
H1299 NVPo[3pKTnWwY4Tpc44hSXO|YYm= NGfGVW0yOCEQvHevcYw> Mlv3NlQhcA>? NVTPTHpkcW6mdXPld{BifXSxcHjh[5nDqA>? NXPTbFc2OjV|OEi5O|A>
MDA-MB-231 NH\PUJhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUGw5qCUPTBizsznM41N NX3SVG1YPDhiaB?= NVj4SIsyTUN3MNMgQUAxNjBzNjFCuYcwdUx? NEDkW5AzPTN3NkW2Oy=>
MDA-MB-231 MnfwRZBweHSxc3nzJGF{e2G7 NVzHSHI4OC5zIN88[{9uVA>? NVrnSY57PCCq MXnpcoR2[2W|IHHwc5B1d3Orcx?= MnzxNlU{PTZ3Nke=
MDA-MB-231 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXQNE4xOS9yLkC1JO69\y:vTB?= MkLTNlQhcA>? M2flS4lv[3KnYYPld{B1cGViZoLhZ5Rqd25ib3[gd5VjNUdzIHPlcIwh\GWkcnnz MWiyOVM2PjV4Nx?=
MDA-MB-231 NYHFSHlbSXCxcITvd4l{KEG|c3H5 MYCwMlA26oDVMTFOwIcwdUx? MUmyOEBp M330fIlv\HWlZYOgVGFTWCBqcH;sfUBCTFBvcnnic5NmKHCxbInt[ZJie2VvMTmgZ4xm[X[jZ3W= MUiyOVM2PjV4Nx?=
MDA-MB-231 MlG4SpVv[3Srb36gRZN{[Xl? Ml:wNQKBmzVyIN88[{9uVA>? NF\ISYIzPCCq MnO3bY5pcWKrdIOgeIhmKG[xcn3heIlwdiCxZjCzSEBidmRiMlSgZ49td26rZYO= MmXwNlU{PTZ3Nke=
A172 MmHnSpVv[3Srb36gRZN{[Xl? MXixNOKh|rypL33s MWG0xsBp M4rC[GROW00EoB?= NY\COFlZemW|dXz0d{BqdiC2aHWgdoV1em:pcnHk[UB1emGwc4DvdpQhd2ZiZnz1c5Jme2OnboSg[5JidnWuZYO= NHHJZoczPTJ|OUWwOy=>
KMS-6 NHfNc4pHfW6ldHnvckBCe3OjeR?= MnHSNeKh|ryPwrC= MYSyOEBp NIrqc|JmgGirYnn0d{Bp[WyoIITo[UB{\WO{ZYTpc44hd2ZiZ3HsZY5qdi2OSTDhd{BlcWRidHjlJINwdnS{b3y= NIDXO3IzPTJ{OUGyOi=>
MEC NGnkdmhHfW6ldHnvckBCe3OjeR?= NEHhVJcyKM7:TR?= NYPTdXJ{OS53IHi= MYXjZZV{\XNiYTDkdoFu[XSrYzDk[YNz\WG|ZTDpckB1cGVic4Xy[oFk\SCYRVfGVlI> NGPLbWMzPTJ{OEixOS=>
HEK293/hERG NXXFSJduTnWwY4Tpc44hSXO|YYm= NIO5T2EyOMLizszN MUOxxsBp Ml3hdoV{fWy2czDpckBiKHSrbXWt[IVx\W6mZX70JJJm\HWldHnvckBu[XS3cnWgbGVTTyCycn;0[YlvyqB? Mn[1NlUzOTh2Nkm=
RBE4 NEH0NHJCeG:ydH;zbZMhSXO|YYm= M1j1c|LDqM7:TR?= MoTSN-KBmzJ2wrDo Mn;jbY5lfWOnczDhdI9xfG:|aYOgeIlu\SCmZYDlcoRmdnSueR?= M4KzelI2OTJ6MEK1
RBE4 MmSySpVv[3Srb36gRZN{[Xl? NVS3cJNIOsLizszN NETxTZk{6oDVMkVCpIg> MknqbY5kemWjc3XzJJRp\SC[QmCxJJBzd3SnaX6gcIV3\Wy|IHHmeIVzKDNiYX7kJFbDqGhib3[geJJm[XSvZX70 MYOyOVEzQDB{NR?=
RBE4 MYXGeY5kfGmxbjDBd5NigQ>? MYKyxsDPxE1? MWKz5qCUOjUEoHi= NE\DVVdqdmO{ZXHz[ZMh[WO2aY\lJINie3Cjc3WtNVIhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZLDqA>? MUSyOVEzQDB{NR?=
RBE4 NUHoRWNVTnWwY4Tpc44hSXO|YYm= NHrlXHgzyqEQvF2= MVyz5qCUOjUEoHi= MoPDbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiUl;TJJRqdWVvZHXw[Y5l\W62bIm= MYiyOVEzQDB{NR?=
RBE4 MX7GeY5kfGmxbjDBd5NigQ>? MUSyxsDPxE1? M1L4clPjiJN{NNMgbC=> M4LGZolv\HWlZYOgZUBl\WyjeXXkJIRmeGyndHnvckBw\iC2aHWgSXIhS2F{K9MgZ49vfGWwdDDheEA3yqCqIH;mJIlv[3WkYYTpc44he2mpbnnmbYNidnSueR?= NUXxV4tVOjVzMkiwNlU>
RBE4 NHzvboRHfW6ldHnvckBCe3OjeR?= MYWyxsDPxE1? NGW2cYs{6oDVMkVCpIg> Mnn4bY5lfWOnczDhckBwfmW{bH;h[EBw\iCFYUKrxsBqdiC2aHWgcYl1d2Oqb37kdoliKGmwIITo[UBncXK|dDC2xsBpKG:oIHnuZ5Vj[XSrb36gLJDjiIl:4pEJNE4xODFrIHL1eEBE[TJtwrDs[ZZmdHNiaX6geIhqeyCxcnfhcoVtdGViZHXjdoVie2WmIHHmeIVzKDF{wrDoJI9nKGmwY4XiZZRqd25? MWKyOVEzQDB{NR?=
Huh-7  NE\HS3NHfW6ldHnvckBCe3OjeR?= NHO3[poy|rypL33M M13hWlPjiJN{NNMgbC=> M4H4dIlv[3KnYYPld{B1cGVibHX2[Ywhd2ZiQWDFNUBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MlHBNlUxOjZzN{S=
HepG2  MX3GeY5kfGmxbjDBd5NigQ>? MkjhNe69\y:vTB?= MX:z5qCUOjUEoHi= NIDqTY1qdmO{ZXHz[ZMhfGinIHzleoVtKG:oIFHQSVEhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MV2yOVAzPjF5NB?=
H838-LKB1 MX3GeY5kfGmxbjDBd5NigQ>? M2K3Z|MxyqCwZz;tcC=> NGPNVYIyOi9zODDo M37RWolv[3KnYYPld{B1cGVicILveIVqdiCuZY\lcJMhd2ZiQnnQxsA> NGnobokzPTBzMUC4Ni=>
H838-KDLKB1  MYnGeY5kfGmxbjDBd5NigQ>? NWm3TG1HOzEEoH7nM41t M4\nOFEzNzF6IHi= NF7BOmNqdmO{ZXHz[ZMhfGinIIDyc5RmcW5ibHX2[Yx{KG:oIFLpVOKh M4rmXFI2ODFzMEiy
H838-KDLKB1  NFXsSHJHfW6ldHnvckBCe3OjeR?= MmPwN|DDqG6pL33s NV[0OmZSOTJxMUigbC=> MUfpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyaH;zdIhwenmuYYTl[EBmUUZ{zsGgLJBpd3OyaH:t[WlHOs7zKR?= NYjyOWNROjVyMUGwPFI>
3T3-L1 MX\GeY5kfGmxbjDBd5NigQ>? NY\RcZV7PSEQvHevcYw> M4fxUFMxKG2rbh?= MYLtbY1q[3NidHjlJIVn\mWldIOgc4YhcW6|dXzpckBidmRiY3H1d4V{KHKxYoXzeEBxcG:|cHjvdplt[XSrb36gc4YhSWu2IDjT[ZIhPDd|KTDhcoQheGixc4Doc5J6dGG2aX;uJI9nKEGVMU[wJEhVcHJiNkSyJIFv\CCVZYKgOVg5MQ>? NUPBXWF6OjR6NEO4Nlc>
3T3-L1 MXfGeY5kfGmxbjDBd5NigQ>? Mnr4OUDPxGdxbXy= MWqzNEBucW5? M2\rbJJm[2GyaYT1cIF1\XNiaX7zeYxqdiCjY4Tpc44hf2m2aDDy[ZNx\WO2IITvJJJm\3WuYYTpcochSWu2IHHjeIl3cXS7IHHu[EBCWzF4MDDwbI9{eGixconsZZRqd25? MlWxNlQ5PDN6Mke=
3T3-L1 M2ridWZ2dmO2aX;uJGF{e2G7 NGLjSIk2KM7:Zz;tcC=> Mn3oN|AhdWmw MWrjZZV{\XNicnX2[ZJ{cWKuZTDy[YRqe3S{aXL1eIlwdiCxZjDHUHVVPA>? MmfENlQ5PDN6Mke=
3T3-L1 NH\K[GhHfW6ldHnvckBCe3OjeR?= NFzHenM2KM7:Zz;tcC=> M3TQWFHDqGh? NUDhPG5K[2G3c3XzJJJm\Gm|dILpZpV1cW:wIH;mJGdNXVR2IHL1eEBvd3RiaX7jdoVie2ViaX6g[4x2[2:|ZTD1dJRic2V? NYfRVGwyOjR6NEO4Nlc>
3T3-L1 MWLGeY5kfGmxbjDBd5NigQ>? MYW1JO69\y:vbB?= MXixxsBp M3vINYNifXOnczDwbI9{eGixconsZZRqd25ib3[geIhmKE[xeF:xJJRz[W6|Y4LpdJRqd25iZnHjeI9z MlPxNlQ5PDN6Mke=
HeLa  NHfW[mlHfW6ldHnvckBCe3OjeR?= MXi1JO69\y:vbB?= MnfaN{Bp M4fIeYNifXOnczDueYNt\WG{IHX4Z4x2e2mxbjDv[kB1cGViRn;4U|EhfHKjboPjdolxfGmxbjDmZYN1d3JiYX7kJIRm[3KnYYPld{B1emGwc3PybZB1cW:wIH;mJGZwgE9zLYLl[5Vt[XSnZDDn[Y5mew>? MVuyOFg1Ozh{Nx?=
HEK293 M1y4cmZ2dmO2aX;uJGF{e2G7 NULZZ5NsPcLizsznM41t NWjBNml{OTMEoHi= M4HRbIFjd2yrc3jld{BEVUFvaX7keYNm\CCFUlXMSFIhe2WlcnX0bY9v MlfNNlQ3QDd2M{G=
COS-1 NWXkeJN1TnWwY4Tpc44hSXO|YYm= MXm1JOK2\y:vbB?= MlXnNlQhcMLi M{LZOpJme3S{aXP0d{Btd2OjbHn6ZZRqd25ib3[gUmIhcW5idHjlJJBmemmwdXPs[YFzKHKnZ3nvcuKh MVuyOFY4OTd3MR?=
PRP NVGwRXhqTnWwY4Tpc44hSXO|YYm= MoTNNVAh|ryP M{DXfIFjem:pYYTld{BUTEZvMd8xMY1m\GmjdHXkJGNZS1J5IHX4eIVzdmGuaYrheIlwdsLi NVvyV5dFOjR4Nki3OVA>
RAW264.7 MVnBdI9xfG:|aYOgRZN{[Xl? M{PNPFQh|ryP NG[0e4I1QCCq M3\YVYF1fGWwdXH0[ZMhfGinIHnubIljcXSrb36gc4Yhd3hvTFTMMYlv\HWlZXSgZZBweHSxc3nzJIFv\CC2aHWg[oFkcWyrdHH0bY9vKG:oIHPoc4xme3Sncn;sJIVn\my3eDDifUBC[y2qRT2xPGEuVkh{ M{nlXlI1PjN7MEOy
MDMs NF3RfIdCeG:ydH;zbZMhSXO|YYm= NXzh[IpPOTEkgJpOwIcwdWx? MVWxNk8yPSCq M{PBeIlv\HWlZYOgZZBweHSxc3nz NFrETnUzPDV3Nk[5OS=>
PMHs  NUW5XohrTnWwY4Tpc44hSXO|YYm= NHnXNW4yOOLCk{Kw5qCK|rypL33s MlHBNlTjiImq M3XLd2ROW09? M{LQUolv\HWlZXSgSXIhe3S{ZYPz MnjDNlQ1ODd{NEK=
PMHs  Mn\NRZBweHSxc3nzJGF{e2G7 MV:xNQKBmzJy4pEJ{txoN22u MmXWNlTjiImq MVjEUXNQ NF\5SW9qdmO{ZXHz[ZMh[2WubDDk[YF1cA>? M2nYelI1PDB5MkSy
HEK293/tau MojnSpVv[3Srb36gRZN{[Xl? M3j3fVUh|ryP NF\kNY8yNzJxNDDo NHW3fY5qdmS3Y3XzJGdwdGerIH\yZYdu\W62YYTpc47DqA>? M1S0fFI1OzZ6MEi5
HEK293/tau MljOSpVv[3Srb36gRZN{[Xl? MX[1JO69VQ>? NUnVZncxOyCq NFnvWIFqdmS3Y3XzJJRifSCqeYDldpBpd3OyaH;yfYxifGmxbh?= NUXhW5g1OjR|NkiwPFk>
ADF MlPOSpVv[3Srb36gRZN{[Xl? NVS2Nnc1OTBizszN MWWxOkBp NWfF[4w5cW6qaXLpeJMhfGinIGruR4wzNWmwZIXj[YQhfHKjboPsc4NifGmxbjDv[kBEWlR? NHXuUG4zPDJ{OEKzNi=>
U373  NFTwTnNHfW6ldHnvckBCe3OjeR?= MYGxNEDPxE1? MnXrNVYhcA>? Mn;PbY5pcWKrdIOgeIhmKFqwQ3yyMYlv\HWlZXSgeJJidnOub3PheIlwdiCxZjDDVnQ> M{nTc|I1OjJ6MkOy
RKO-HIPK2i M1rHT2Z2dmO2aX;uJGF{e2G7 NG\WVJcyOCEQvF2= NY[wUo81OTZiaB?= M1TTcIlvcGmkaYTzJJRp\SCcblPsNk1qdmS3Y3XkJJRz[W6|bH;jZZRqd25ib3[gR3JV MVmyOFIzQDJ|Mh?=
ADF  NV2xUnBxTnWwY4Tpc44hSXO|YYm= M{XydVExKM7:TdMg Mmj0OkBp NYf3ZlVbcW2yYXnyd{B1cGViRFOgZYN1cX[jdHnvci=> MnuxNlQzOjh{M{K=
Huh7 Mm\aSpVv[3Srb36gRZN{[Xl? NFfIOFc2KM7:Zz;tcC=> NGGzXYI1KGh? Mk\hZYJwdGm|aHXzJJRp\SC|ZXPy[ZRqd25ib3[gJIlvfHKjY3XscJVt[XJiQYDvRi=> NIHK[HIzPDFyMEG0NC=>
Huh7 M3jMe2Z2dmO2aX;uJGF{e2G7 NEDTc5M2KM7:Zz;tcC=> MoP3NUBp NEW4SlFk[XW|ZYOgZUB{cWewaX\pZ4FvfCCrbnPy[YF{\SCrbjDBdI9DNWO{ZYPj[Y51ew>? M33FZ|I1OTByMUSw
Huh7 MU\GeY5kfGmxbjDBd5NigQ>? NFfwbpE26oDVMUFCpI5oN22u Mly1NVIhcA>? M1jpXolv[3KnYYPld{BCeG:ELXPy[ZNk\W62czD3bZRpd3W2IHnubIljcXSrbnegd4VkemW2aX;u Ml\PNlQyODBzNEC=
BAECs NXrzVlh{TnWwY4Tpc44hSXO|YYm= M3XCWVUh|rypL33s Mn\nNE01KGh? NFPKT3lqdmS3Y3XzJJRp\SC{YYDp[EBl\XCqb4PwbI9zgWyjdHnvckBw\iCnTl;TJIF1KFOnckGxO|k> MYKyOFA5PTJ{NR?=
Macrophages M{XnXmZ2dmO2aX;uJGF{e2G7 M3nkNVcyKML3TR?= NF;FR4Q3KGh? NIG0ZVJqdmirYnn0d{BtfW6jc3nuJIlvfGW{bnHsbZpifGmxbtMg NWfvfFNrOjRyM{m3OFA>
Colo 205 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TFOFAuPSEQvHevcWw> MlTnOFghcA>? NYPpUWtocW6qaXLpeJMh[2WubDDndo94fGhiaX6gd5V{eGWwc3nvckBkfWy2dYLld{B4cXSqIHHuJIV{fGmvYYTl[EBKSzVyIH;mJJ4yPSCwZz;tUC=> NHnUT5EzOzl5M{m5Oi=>
Colo 205 NFe1Z2xHfW6ldHnvckBCe3OjeR?= NV3FVo9pOC5yMUKtNE4xOjVizsznM41N MWOxOEBl MnHydoVlfWOnczD0bIUh[2yxbn;n[Y5q[2m2eTDv[kBEd2yxIEKwOUBEW0O| MnG1NlM6PzN7OU[=
Colo 205 NGSwcFBCeG:ydH;zbZMhSXO|YYm= NEfMVnUxNjFizsznM41N NGrLOYExNTJ2IHi= NF74coZqdmS3Y3XzJIFxd3C2b4Ppd{Bw\iCFb3zvJFIxPSClZXzsd{BqdiC|dYPw[Y5{cW:wIHP1cJR2emW| MVWyN|k4Ozl7Nh?=
Colo 205 MoTFSpVv[3Srb36gRZN{[Xl? NW\zVphkOC5yMUWg{txoN22O NHT0V5IzPCCq MnLQbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDFVkB{fHKnc4OtdoVt[XSnZDDn[Y5mew>? NVfF[XJJOjN7N{O5PVY>
Colo 205 MXjGeY5kfGmxbjDBd5NigQ>? M1XMUFAvODF3IN88[{9uVA>? M1X6VVI1KGh? MWfpcohq[mm2czD0bIUh[WO2aY\peJkhd2ZiTV3Qdy=> MWGyN|k4Ozl7Nh?=
IBRS2 NHzwPHlHfW6ldHnvckBCe3OjeR?= MnHHOUDPxGdxbXy= NXvId41rOC53IHi= MX7EUXNQ MVPkbZNzfXC2czD0bIUhTVKJSVOgZY5lKEexbHfpxsA> NIXhdpUzOzl4M{WzOC=>
IBRS2 NG\xbmJHfW6ldHnvckBCe3OjeR?= M1iyXVUh|rypL33s NFH3fGYxNjViaB?= MXTEUXNQ NFXaUVRmdmijbnPld{BHVUSYIHnu[oVkfGmxbh?= NUj6T4NPOjN7NkO1N|Q>
HeLa MnnVSpVv[3Srb36gRZN{[Xl? MmrmNkDPxE1? NWnUO|R1OiCqwrC= NWPk[Yl6[XS2ZX71ZZRmeyC2aHWgWG5HNWmwZIXj[YQhe2WlcnX0bY9vKG:oIFnMMVE2 NHjiUGMzOzl3MEi5Ni=>
HFS  NHvv[2JHfW6ldHnvckBCe3OjeR?= M{f4dVAuOSEQvHevcYw> MnTONlQhcA>? MULHUHRRKGW6cILld5Nqd25icnXhZ4hmeyCjIIDsZZRm[XViYYSgZ49v[2WwdILheIlwdnNiYYOgcI94KGG|IECuNFEhyrWpL33s NIf2[HkzOzh7NE[zNy=>
HFS  MofESpVv[3Srb36gRZN{[Xl? MV2wMlAyKML3Zz;tcC=> NXO5PHFbOjRiaB?= MXrpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[g[4x6[2:|cHjpcodwdGmyaXSgd5lvfGijc3Wg[4Vv\XNiYYSgOkBp M{nNU|I{QDl2NkOz
OVCAR-3 MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjOclky6oDVMUZCpO69VcLi MmrQNlTDqGh? NV7IeJBMcW6mdXPld{BiKGyxc4Ogc4Yh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSuedMg NI\yXo4zOzh{Nkm2OC=>
OVCAR-3 MWLGeY5kfGmxbjDBd5NigQ>? Ml7aNgKBmzF3wrFOwG3DqA>? MkXONlTDqGh? MYDpcoR2[2W|IH71Z4xm[XJiZHHtZYdm M3XDOlI{QDJ4OU[0
OVCAR-3 NHfUTllCeG:ydH;zbZMhSXO|YYm= NHPqT3MyNTFywrFOwG0> MknTOEBp M3jDdYlv\HWlZYOgeIhmKGGldHn2ZZRqd25ib3[gZZBweHSxc3nzMZJmdGG2ZXSgdJJwfGWrboO= NX\he|gzOjN6Mk[5OlQ>
OVCAR-3 MleyRZBweHSxc3nzJGF{e2G7 MXOxNOKh|ryP MUiyOOKhcA>? NILpdHNqdmS3Y3XzJIFkfGm4YYTpc44hd2ZiY3HzdIF{\XN? MWCyN|gzPjl4NB?=
OVCAR-3 M2O2U2Z2dmO2aX;uJGF{e2G7 M{WyXlHjiJNzMNMg{txO MVuyOOKhcA>? NUCySFhScW6mdXPld{BlcXO{dYD0bY9vKG:oIITo[UBucXSxY3jvcoRzcWGuIITyZY5{dWWvYoLhcoUheG:2ZX70bYFt MV2yN|gzPjl4NB?=
OVCAR-3 M3HzPGZ2dmO2aX;uJGF{e2G7 NXvGTXB3OeLCk{GwxsDPxE1? NIHtdlkzPMLiaB?= NE\kTGdqdmS3Y3XzJIZwem2jdHnvckBw\iC{ZXHjeIl3\SCxeInn[Y4he3CnY3nldy=> M17oNVI{QDJ4OU[0
OVCAR-3 NFXW[YdHfW6ldHnvckBCe3OjeR?= M3fJdlHjiJNzMNMg{txO MWiyOOKhcA>? M{XLOYlvcGmkaYTzJINmdGxiYXTo[ZNqd25iYX7kJI1q\3KjdHnvci=> Mn;NNlM5OjZ7NkS=
MKN45 M4mwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnqPIFVUUN3MEywMlAxOSEQvHevcYw> M3riZlI{Pzl|M{Sy
LOVO NFO5NIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPzTWM2OD1yLkGyJO69\y:vbB?= NWHnfmttOjN5OUOzOFI>
A549 MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3qTWM2OD1yLkC0JO69\y:vbB?= M3fUZlI{Pzl|M{Sy
MDA-MB-435 M363dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRDBwMECxJO69\y:vbB?= MlzPNlM4QTN|NEK=
HepG2 NYn0eJNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRDBwMECxJO69\y:vbB?= NX;wd21OOjN5OUOzOFI>
HL-60 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPSOolNUUN3MEywMlAxOSEQvHevcYw> M{H4Z|I{Pzl|M{Sy

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[5]
+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method: HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID